Valopicitabine dihydrochloride: A specific polymerase inhibitor of hepatitis C virus

Pierluigi Toniutto; Carlo Fabris; Davide Bitetto; Ezio Fornasiere; Rachele Rapetti; Mario Pirisi

Valopicitabine dihydrochloride: A specific polymerase inhibitor of hepatitis C virus

Pierluigi Toniutto, Carlo Fabris, Davide Bitetto, Ezio Fornasiere, Rachele Rapetti, Mario Pirisi

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

Idenix Pharmaceuticals Inc and Novartis AG are codeveloping valopicitabine dihydrochloride, a once-daily oral nucleoside for the potential treatment of HCV infection. In January 2005, a phase IIa clinical trial comparing valopicitabine dihydrochloride with pegylated IFN in treatment-naive HCV patients was ongoing, in addition to a phase IIb trial in patients that had previously failed pegylated IFN and ribavirin combination therapy. In January 2006, an international phase III trial in treatment-refractory patients was planned for the first half of the year, with a phase III trial in treatment-naive individuals planned for the second half of the year.

Lingua originale	Inglese
pagine (da-a)	150-158
Numero di pagine	9
Rivista	Current Opinion in Investigational Drugs
Volume	8
Numero di pubblicazione	2
Stato di pubblicazione	Pubblicato - feb 2007
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{29d7500a823945cb86906aeca58f6bd7,

title = "Valopicitabine dihydrochloride: A specific polymerase inhibitor of hepatitis C virus",

abstract = "Idenix Pharmaceuticals Inc and Novartis AG are codeveloping valopicitabine dihydrochloride, a once-daily oral nucleoside for the potential treatment of HCV infection. In January 2005, a phase IIa clinical trial comparing valopicitabine dihydrochloride with pegylated IFN in treatment-naive HCV patients was ongoing, in addition to a phase IIb trial in patients that had previously failed pegylated IFN and ribavirin combination therapy. In January 2006, an international phase III trial in treatment-refractory patients was planned for the first half of the year, with a phase III trial in treatment-naive individuals planned for the second half of the year.",

author = "Pierluigi Toniutto and Carlo Fabris and Davide Bitetto and Ezio Fornasiere and Rachele Rapetti and Mario Pirisi",

year = "2007",

month = feb,

language = "English",

volume = "8",

pages = "150--158",

journal = "Current Opinion in Investigational Drugs",

issn = "1472-4472",

number = "2",

}

TY - JOUR

T1 - Valopicitabine dihydrochloride

T2 - A specific polymerase inhibitor of hepatitis C virus

AU - Toniutto, Pierluigi

AU - Fabris, Carlo

AU - Bitetto, Davide

AU - Fornasiere, Ezio

AU - Rapetti, Rachele

AU - Pirisi, Mario

PY - 2007/2

Y1 - 2007/2

N2 - Idenix Pharmaceuticals Inc and Novartis AG are codeveloping valopicitabine dihydrochloride, a once-daily oral nucleoside for the potential treatment of HCV infection. In January 2005, a phase IIa clinical trial comparing valopicitabine dihydrochloride with pegylated IFN in treatment-naive HCV patients was ongoing, in addition to a phase IIb trial in patients that had previously failed pegylated IFN and ribavirin combination therapy. In January 2006, an international phase III trial in treatment-refractory patients was planned for the first half of the year, with a phase III trial in treatment-naive individuals planned for the second half of the year.

AB - Idenix Pharmaceuticals Inc and Novartis AG are codeveloping valopicitabine dihydrochloride, a once-daily oral nucleoside for the potential treatment of HCV infection. In January 2005, a phase IIa clinical trial comparing valopicitabine dihydrochloride with pegylated IFN in treatment-naive HCV patients was ongoing, in addition to a phase IIb trial in patients that had previously failed pegylated IFN and ribavirin combination therapy. In January 2006, an international phase III trial in treatment-refractory patients was planned for the first half of the year, with a phase III trial in treatment-naive individuals planned for the second half of the year.

UR - http://www.scopus.com/inward/record.url?scp=33947309390&partnerID=8YFLogxK

M3 - Review article

SN - 1472-4472

VL - 8

SP - 150

EP - 158

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

IS - 2

ER -

Valopicitabine dihydrochloride: A specific polymerase inhibitor of hepatitis C virus

Abstract

OSS delle Nazioni Unite

Altri file e collegamenti

Fingerprint

Cita questo